Skip to content

Pets

Is CBD safe for dogs? What the published studies measured

Written by: Author pendingReviewed by: Reviewer pendingUpdated:

Answer

The published canine studies report CBD as well tolerated at 2 mg/kg twice daily for up to 12 weeks, with loose stool the most common effect and liver enzyme elevations the main value to watch (Animals, 2019). FDA has not approved cannabis for any use in animals, and product quality, not the molecule, is the biggest documented risk.

"Safe" is a regulatory word, and no regulator has applied it to CBD in dogs. What exists instead is a small set of controlled studies that measured what happened when healthy dogs took CBD at known doses for known periods. This page reports what those studies found and what they did not test.

What did the dosing studies record?

Answer

The longest controlled exposure is a 12-week study in Animals. Eight beagles received 2 mg/kg of CBD twice daily as a soft chew. Across 1,344 observation periods the researchers logged 53 adverse events, with loose stool in about 3.3 percent of observations and vomiting in 0.45 percent. Blood work showed no clinically significant changes, and no dog's alkaline phosphatase left the reference range.

The widest dose range comes from a 2020 escalation study in Frontiers in Veterinary Science. Twenty beagles received CBD oil, THC oil, a CBD/THC blend or placebo at rising doses; the CBD group climbed to about 62 mg/kg, roughly 30 times the common study dose. Of 505 adverse events across all groups, 94.9 percent were mild, and the CBD-only group had no moderate or severe events, a profile comparable to the MCT-oil placebo. The moderate and severe events, including ataxia, lethargy and low body temperature, clustered in the groups that received THC.

The Merck Veterinary Manual summarizes real-world exposure data from Pet Poison Helpline cases between 2018 and 2023: about 45 percent of CBD cases remained clinically normal, with vomiting in 15 percent and lethargy in 30 percent. Merck's framing is that overdose "could lead, at most, to 'GI distress'" and that signs are self-limiting.

What is the one lab value the studies flagged?

Answer

Liver enzymes, specifically alkaline phosphatase (ALP). In the 2018 Cornell trial, ALP rose significantly over 4 weeks of 2 mg/kg dosing, with increases in 9 of 16 dogs; the authors called the clinical significance uncertain and recommended monitoring. In the escalation study, one CBD-group dog's ALP reached 2.9 times baseline after the highest dose, stayed within the reference limit, and fell within 7 days. Merck notes chronic dosing in dogs produces transient ALP elevations, possibly from enzyme induction, and that liver enzyme monitoring may be indicated with long-term use.

The practical reading: ALP changes were common, mild and reversible in the studies, and no study followed dogs beyond 12 weeks. A dog on daily CBD for months is outside the published data, which is a reason for periodic blood work rather than a reason for alarm.

What do FDA and the veterinary profession say?

Answer

FDA's statement is categorical: "FDA has not approved cannabis for any use in animals", and the agency says it cannot ensure the safety or effectiveness of these products and cautions pet owners against their use. A 2021 review in Animals is more measured, concluding that the available data suggest CBD may be well tolerated by animals while stressing that few studies have examined safety and that product quality control is poor.

Those two positions are not in conflict. One is about approval, which requires evidence no company has submitted. The other is about tolerance at studied doses, which the data support. Both agree the gap is in the products.

What is the actual risk, then?

Answer

The bottle, more than the molecule. Merck reports that in the Pet Poison Helpline dataset, THC-containing products accounted for 90 percent of cannabinoid cases and CBD-predominant products 10 percent, and that signs more typical of THC in a dog given a "CBD" product point to unlabeled THC or poor manufacturing. A current certificate of analysis showing ND for THC, a listed limit of quantitation, and potency matching the label is the single document that moves a dog product from the risky category to the studied one. Dogs on other prescriptions, dogs with liver conditions and puppies were not in any of these studies, and a veterinarian should be in the loop for them.

This page is general information, not personalized guidance.

General information, not personalized guidance.

Sources

  1. Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats Animals (Basel), via PubMed Central (accessed 2026-10-13)
  2. Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs Frontiers in Veterinary Science (accessed 2026-10-13)
  3. Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs Frontiers in Veterinary Science (accessed 2026-10-13)
  4. Toxicosis in Dogs and Cats From Cannabidiol (CBD) Merck Veterinary Manual (accessed 2026-10-13)
  5. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD) U.S. Food and Drug Administration (accessed 2026-10-13)
  6. Cannabis, Cannabidiol Oils and Tetrahydrocannabinol: What Do Veterinarians Need to Know? Animals (Basel), via PubMed Central (accessed 2026-10-13)

Adults 21 and older

Are you 21 or older?

This store sells kratom and kava products to adults 21 and older. Every order is age-verified at checkout against public records, with a photo ID fallback. By continuing you confirm you are at least 21.